Drugs / RAGWEED
last change Apr 2022 re-read 2 minutes ago

RAGWEED

Developed for
hypersensitivity reaction disease
Investigated by
Cuneyt M. Alper · National Institute on Deafness and Other Communication Disorders (NIDCD)

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01925729 Oct 2013 → Mar 2019 allergic rhinitis, otitis media Cuneyt M. Alper Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT05119751 Comparator Oct 2021 → Apr 2022 hypersensitivity reaction disease Clinique Spécialisée en Allergies de la Capitale Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ragweed ClinicalTrials.gov intervention name — accepted as the source's own label NCT01925729
1

NCT05119751

Route Intranasal “ragweed -- 1000PNU intranasal spray” NCT01925729